{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:34:07Z","timestamp":1786995247823,"version":"build-2736575974"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T00:00:00Z","timestamp":1559692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-133639"],"award-info":[{"award-number":["MOP-133639"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN-143213"],"award-info":[{"award-number":["FDN-143213"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.omtm.2019.05.013","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T20:27:33Z","timestamp":1559939253000},"page":"90-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Generation of High-Titer Self-Inactivated \u03b3-Retroviral Vector Producer Cells"],"prefix":"10.1016","volume":"14","author":[{"given":"Karim","family":"Ghani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boivin-Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dakiw-Piaceski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Barbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2019.05.013_bib1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0092-8674(83)90344-6","article-title":"Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus","volume":"33","author":"Mann","year":"1983","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2019.05.013_bib2","first-page":"4239","article-title":"Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection","volume":"10","author":"Miller","year":"1990","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.omtm.2019.05.013_bib3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.2174\/156652310793797739","article-title":"Production of retroviral vectors: review","volume":"10","author":"Coroadinha","year":"2010","journal-title":"Curr. Gene Ther."},{"issue":"R1","key":"10.1016\/j.omtm.2019.05.013_bib4","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1093\/hmg\/ddv451","article-title":"Progress and challenges in viral vector manufacturing","volume":"25","author":"van der Loo","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2019.05.013_bib5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.15252\/emmm.201707573","article-title":"Gene therapy for ADA-SCID, the first marketing approval of an ex\u00a0vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products","volume":"9","author":"Aiuti","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2019.05.013_bib6","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1089\/hum.2017.110","article-title":"Twenty years of European Union support to gene therapy and gene transfer","volume":"28","author":"Gancberg","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2019.05.013_bib7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11095-018-2436-z","article-title":"Chimeric antigen receptor T-cells (CAR T-cells) for cancer immunotherapy - moving target for industry?","volume":"35","author":"Salmikangas","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.omtm.2019.05.013_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","author":"Brudno","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omtm.2019.05.013_bib9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fphar.2015.00095","article-title":"Improving the safety of cell therapy with the TK-suicide gene","volume":"6","author":"Greco","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omtm.2019.05.013_bib10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease","volume":"288","author":"Cavazzana-Calvo","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.omtm.2019.05.013_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1089\/hum.2015.137","article-title":"Gene therapy for X-linked severe combined immunodeficiency: where do we stand?","volume":"27","author":"Cavazzana","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2019.05.013_bib12","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa012616","article-title":"Sustained correction of X-linked severe combined immunodeficiency by ex\u00a0vivo gene therapy","volume":"346","author":"Hacein-Bey-Abina","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2019.05.013_bib13","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2019.05.013_bib14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T\u00a0cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.omtm.2019.05.013_bib15","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2019.05.013_bib16","doi-asserted-by":"crossref","first-page":"227ra33","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2019.05.013_bib17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm1393","article-title":"Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1","volume":"12","author":"Ott","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2019.05.013_bib18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2019.05.013_bib19","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1182\/blood-2009-02-202085","article-title":"Integration of retroviral vectors induces minor changes in the transcriptional activity of T\u00a0cells from ADA-SCID patients treated with gene therapy","volume":"114","author":"Cassani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2019.05.013_bib20","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1182\/blood-2005-08-024976","article-title":"Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity","volume":"108","author":"Modlich","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2019.05.013_bib21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nbt1216","article-title":"Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration","volume":"24","author":"Montini","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2019.05.013_bib22","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/mt.2009.179","article-title":"Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors","volume":"17","author":"Modlich","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.05.013_bib23","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/mt.2008.5","article-title":"Physiological promoters reduce the genotoxic risk of integrating gene vectors","volume":"16","author":"Zychlinski","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.05.013_bib24","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1172\/JCI37630","article-title":"The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy","volume":"119","author":"Montini","year":"2009","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2019.05.013_bib25","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1404588","article-title":"A modified \u03b3-retrovirus vector for X-linked severe combined immunodeficiency","volume":"371","author":"Hacein-Bey-Abina","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2019.05.013_bib26","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.omtm.2019.05.013_bib27","doi-asserted-by":"crossref","first-page":"1233151","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.omtm.2019.05.013_bib28","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent \u03b2-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2019.05.013_bib29","doi-asserted-by":"crossref","first-page":"16017","DOI":"10.1038\/mtm.2016.17","article-title":"Production of lentiviral vectors","volume":"3","author":"Merten","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2019.05.013_bib30","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/gt.2011.102","article-title":"Scale-up and manufacturing of clinical-grade self-inactivating \u03b3-retroviral vectors by transient transfection","volume":"19","author":"van der Loo","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2019.05.013_bib31","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/sj.gt.3303039","article-title":"Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media","volume":"14","author":"Ghani","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2019.05.013_bib32","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1089\/hum.2009.001","article-title":"Efficient human hematopoietic cell transduction using RD114- and GALV-pseudotyped retroviral vectors produced in suspension and serum-free media","volume":"20","author":"Ghani","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2019.05.013_bib33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/CJI.0000000000000072","article-title":"Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor","volume":"38","author":"Wang","year":"2015","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omtm.2019.05.013_bib34","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3389\/fimmu.2018.01062","article-title":"GMP-grade manufacturing of T\u00a0cells engineered to express a defined \u03b3\u03b4TCR","volume":"9","author":"Straetemans","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2019.05.013_bib35","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/sj.gt.3302807","article-title":"Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors","volume":"13","author":"Schambach","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2019.05.013_bib36","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2019.05.013_bib37","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1099\/vir.0.020255-0","article-title":"High-titre retroviral vector system for efficient gene delivery into human and mouse cells of haematopoietic and lymphocytic lineages","volume":"91","author":"Wu","year":"2010","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.omtm.2019.05.013_bib38","doi-asserted-by":"crossref","first-page":"6733","DOI":"10.1073\/pnas.92.15.6733","article-title":"Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells","volume":"92","author":"Rivi\u00e8re","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2019.05.013_bib39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0378-1119(91)90434-D","article-title":"Efficient selection for high-expression transfectants with a novel eukaryotic vector","volume":"108","author":"Niwa","year":"1991","journal-title":"Gene"},{"key":"10.1016\/j.omtm.2019.05.013_bib40","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1128\/JVI.76.14.7209-7219.2002","article-title":"RNA 3\u2032 readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy","volume":"76","author":"Zaiss","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2019.05.013_bib41","doi-asserted-by":"crossref","first-page":"9211","DOI":"10.1073\/pnas.83.23.9211","article-title":"Nondefective spleen necrosis virus-derived vectors define the upper size limit for packaging reticuloendotheliosis viruses","volume":"83","author":"G\u00e9linas","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2019.05.013_bib42","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/mt.2010.91","article-title":"SIN retroviral vectors expressing COL7A1 under human promoters for ex\u00a0vivo gene therapy of recessive dystrophic epidermolysis bullosa","volume":"18","author":"Titeux","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.05.013_bib43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.22203\/eCM.v035a06","article-title":"Translating the combination of gene therapy and tissue engineering for treating recessive dystrophic epidermolysis bullosa","volume":"35","author":"Dakiw Piaceski","year":"2018","journal-title":"Eur. Cell. Mater."},{"key":"10.1016\/j.omtm.2019.05.013_bib44","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1525-0016(03)00011-X","article-title":"A SIN lentiviral vector containing PIGA cDNA allows long-term phenotypic correction of CD34+-derived cells from patients with paroxysmal nocturnal hemoglobinuria","volume":"7","author":"Robert","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.05.013_bib45","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1073\/pnas.0507496103","article-title":"Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T\u00a0cells","volume":"103","author":"Recchia","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2019.05.013_bib46","doi-asserted-by":"crossref","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T\u00a0cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2019.05.013_bib47","doi-asserted-by":"crossref","first-page":"20158","DOI":"10.1074\/jbc.M113.545855","article-title":"The U3 region of Moloney murine leukemia virus contains position-independent cis-acting sequences involved in the nuclear export of full-length viral transcripts","volume":"289","author":"Volkova","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2019.05.013_bib48","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1073\/pnas.84.5.1197","article-title":"A promoterless retroviral vector indicates that there are sequences in U3 required for 3\u2032 RNA processing","volume":"84","author":"Dougherty","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2019.05.013_bib49","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1128\/JVI.73.4.2886-2892.1999","article-title":"Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors","volume":"73","author":"Zufferey","year":"1999","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2019.05.013_bib50","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.gene.2005.12.018","article-title":"WPRE-mediated enhancement of gene expression is promoter and cell line specific","volume":"372","author":"Klein","year":"2006","journal-title":"Gene"},{"key":"10.1016\/j.omtm.2019.05.013_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2005.06.037","article-title":"Effect of posttranscriptional regulatory elements on transgene expression and virus production in the context of retrovirus vectors","volume":"341","author":"Hlavaty","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.omtm.2019.05.013_bib52","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/sj.gt.3302979","article-title":"The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors","volume":"14","author":"Higashimoto","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2019.05.013_bib53","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1089\/104303401753153947","article-title":"Systematic determination of the packaging limit of lentiviral vectors","volume":"12","author":"Kumar","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2019.05.013_bib54","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/hgtb.2014.071","article-title":"Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating \u03b3-retroviral vectors","volume":"25","author":"Feldman","year":"2014","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.omtm.2019.05.013_bib55","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1089\/humc.2014.083","article-title":"HEK293-based production platform for \u03b3-retroviral (self-inactivating) vectors: application for safe and efficient transfer of COL7A1 cDNA","volume":"25","author":"Hennig","year":"2014","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.omtm.2019.05.013_bib56","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.omtm.2019.05.013_bib57","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10616-006-9028-1","article-title":"Optimization of an electroporation protocol using the K562 cell line as a model: role of cell cycle phase and cytoplasmic DNAses","volume":"51","author":"Delgado-Ca\u00f1edo","year":"2006","journal-title":"Cytotechnology"}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050119300579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050119300579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:52:06Z","timestamp":1778867526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050119300579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":57,"alternative-id":["S2329050119300579"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2019.05.013","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generation of High-Titer Self-Inactivated \u03b3-Retroviral Vector Producer Cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2019.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}